Modulation of protective and pathological immunity in mycobacterial infections

International Archives of Allergy and Immunology

Volumn 113, Issue 4, 1997, Pages 400-408

  Ottenhoff, Tom H M ^a   Spierings, Eric ^a   Nibbering, Peter H ^a   De Jong, Rolien ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immune modulation; Immunopathology; Mycobacterial disease; Schwann cells; T cell subsets

Indexed keywords

CD4 ANTIGEN; CYTOKINE;

BACILLUS; HELPER CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; LEPROSY; MORBIDITY; MORTALITY; MYCOBACTERIOSIS; NERVE INJURY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINATION;

EID: 0030804982     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237615     Document Type: Article

References (70)

1. WHO Report on the Tuberculosis Epidemic. Geneva, WHO, 1996.
2. Hopewell PC: Overview of clinical tuberculosis; in Bloom BR (cd): Tuberculosis: Pathogenesis, Protection and Control. Washington, ASM Press. 1994. pp 25-46.
3. Mosmann TR, Coffman RL, Seder RA, et al: Thl and Th2 cells: different patterns of lympho-kinc secretion lead to different functional properties. Acquisition of lymphokine-produeing phenotype by CD4+ T cells B7-1 and B7-2 costimulatory molecules activate differentially the Th!/Th2 developmental pathways: Application to autoimmune disease therapy. Annu Rev Immunol 1995;80:707-718.
4. Seder RA, Paul WE: Acquisition of lympho-kine-producing phenotype by 04+ T cells. Annu Rev Immunol 1994:12:635-673.
5. Kuchroo VK, Das MP, Brown JA, et al: Acquisition of lymphokine-produeing phenotype by CD4+ T cells B7-I and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995:80:707-718.
6. Liblau RS, Singer SM, McDevitt HO: Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-38.
7. Chen Y, Kuchroo VK, Inobe J, Ilafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994:265:1237-1240.
8. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM: Development of Till CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993:260: 547-549.
9. Afonso IC, Scharton TM, Vieira LQ, Wysocka M, Trinchicri G, Scott P: The adjuvant effect of interleukin-12 in a vaccine against Leislimania major.Science 1994;263:235-237.
10. Seder RA, Paul WE, Davis MM, Fazekas de St Groth B: The presence of interleukin-4 during in vitro priming determines the lymphokine-produeing potential ofCD4+T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091-1098.
11. Paul WE, Seder RA: Lymphocyte responses and cytokines. Cell 1994:76:241-251.
12. 1" w CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994:179:589-600.
13. Orme IM, Collins FM: Mouse model of tuberculosis; in Bloom RB (ed): Tuberculosis: Pathogenesis. Protection and Control. Washington. ASM Press. 1994, pp 113-134.
14. Kaufmann SH: Immunity to intracellular bacteria. Annu Rev Immunol 1993; 11:129-163.
15. Orme IM, Miller ES, Roberts AD, et al: T lymphocytes mediating protection and cellular cy-tolysis during the course of Mycobacterium tuberculosis infection. Evidence for different kinetics and recognition of a wide spectrum of protein antigens. J Immunol 1992:148:189-196.
16. Orme IM: The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis. J Immunol 1987;138:293-298.
17. ladel CH, Daugelat S, Kaufmann SH: Immune response to Mycobacterium bovis bacille Cal-mette-Guerin infection in major histocompatibility complex class I- and 11-deficient knockout mice: Contribution of CD4 and CDS T cells to acquired resistance. EurJ Immunol 1995:25: 377-384.
18. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR: Major histocompatibility complex class I-restricted T cells arc required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992:89:12013-12017.
19. Ladel CH, Less J, Daugelat S, Mombaerts P, To-ncgawa S, Kaufmann SH: Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette-Gucrin: Studies with T cell receptor-deficient mutant mice. EurJ Immunol 1995: 25.838-846.
20. Ottenhoff TH, Mutis T: Role of cytotoxic cells in the protective immunity against and immu-nopathology of intracellular infections. Eur J Clin Invest 1995:25:371-377.
21. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM: Disseminated tuberculosis in intcrferon-gamma gene-disrupted mice. J Exp Med 1993;178:2243-2247.
22. Flynn JL, Chan J, Triebold KJ, Dalton DK, Steward TA, Bloom BR: An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-2254.
23. Flynn JL, Goldstein MM, Chan J, et al: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995:2:561-572.
24. Flynn JL, Goldstein MM, Triebold KJ, Sypck J, Wolf S, Bloom BR: IL-12 increases resistance of BAl.B/e mice to Mycobacterium tuberculosis infection. J Immunol 1995;155:2515-2524.
25. Ottenhoff TH, Ncuteboom S, Elferink DG, de Vries RR: Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients. J Exp Med 1986;164:1923-1939.
26. Haanen JB, de Waal Malefijt R, Res PC, et al: Selection of a human T helper type I -like T cell subset by mycobacteria. J Exp Med 1991:174: 583-592.
27. Mutis T, Kraakman EM, Cornelisse YE, et al: Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonrcsponsivencss of peripheral blood T cells from lepromatous leprosy patients. J Immunol 1993:150:4641-4651.
28. Ottenhoff TH: Immunology of leprosy: Lessons from and for leprosy. Int J Lepr Other My-cobactDis 1994:62:108-121.
29. Holland SM, Eisenstein EM, Kuhns DB, et al: Treatment of refractory disseminated nontuber-culoas mycobacterial infection with interferon-gamma. A preliminary report. N Engl J Med 1994:330:1348-1355.
30. Levin M, Newport MJ, D’Souza S, et al: Familial disseminated atypical mycobacterial infection in childhood: A human mycobacterial susceptibility gene? Lancet 1995:345:79-83.
31. Frucht DM, Holland SM: Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: Abnormal IL-12 regulation. J Immunol 1996:157:411-416.
32. Newport MJ, Huxley CM, Huston S, Hawry-lowicz CM, Oostra BA, Williamson R, Levin M: A mutation in the intcrfcron-Y-reccptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-1961.
33. Jouanguy E, Altare F, Lamhamedi S, Revy P, Entile J, Newport M, Levin M, Blanche S, Se-boun E, Fischer A, Casanova J: Interferon-y-rc-ceptor deficiency in an infant with fatal bacille Calmette-Gucrin infection. N Engl J Med 1996: 335:1956-1961.
34. Turner J, Dockrell HM: Stimulation of human peripheral blood mononuclear cells with live Mycobacterium hovis BCO activates cytolytic CD8+ T cells in vitro. Immunology 1996:87: 339-342.
35. Kaleab B, Ottenoff T, Converse P, et al: Mycobacterial-induced cytotoxic T cells as well as nonspecific killer cells derived from healthy individuals and leprosy patients. Eur J Immunol 1990;20:2651-2659.
36. Sicling PA, Chatterjce D, Porcelli SA, et al: CD I-restricted T cell recognition of microbial lipoglycan antigens. Science 1995:269:227-230.
37. Morita CT, Beckman EM, Bukowski JF, et al: Direct presentation of nonpeptidc prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 1995:3:495-507.
38. Cooper CL, Mueller C, Sinchaisri TA, Pirmes C, Chan J, Kaplan G, Young SM, Weissman IL, Bloom BR, Rea TH, et al: Analysis of naturally occurring dclayed-type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 1989;169:1565-1581.
39. Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, Modlin RL: Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992:149:1470-1475.
40. Bergsteinsdottir K, Kingston A, Jessen KR: Rat Schwann cells can be induced to express major histocompatibility complex class II molecules in vivo. J Neurocytol 1992;21:382-390.
41. Lisak RP, Bcalmear B: Differences in the capacity of gamma-interferons from different species to induce class 1 and II major histocompatibility complex antigens on neonatal rat Schwann cells in vitro. Pathobiology 1992:60:322-329.
42. Wekerle H, Schwab M, Linington C, Meyer-mann R: Antigen presentation in the peripheral nervous system: Schwann cells present endogenous mo autoantigens to lymphocytes. Eur J Immunol 1986;16:1551-1557.
43. Argall KG, Armati PJ, Pollard JD, Watson E, Bonner J: Interactions between CD4+ T-cells and rat Schwann cells to P2-specific CD4 - T-cell lines. J Ncuroimmunol 1992;40:118.
44. Gold R, Toyka KV, Hartung IIP: Synergistic effect of IFN-y and TN'F-a on expression of immune molecules and antigen presentation by Schwann cells. Cell Immunol 1995:165:65-70.
45. Ford AL, Britton WJ, Armati PJ: Schwann cells are able to present exogenous mycobacterial hsp70 to antigen-specific T lymphocytes. J Ncuroimmunol 1993:43:151-159.
46. Steinhoff U, Schocl B, Kaufmann SH: Lysis of IFN-y-activated Schwann cell by cross-reactive CD8+ u/ß T cells with specificity to the mycobacterial 65-kD heat shock protein. Int Immunol 1990:2:279-284.
47. Bergsteinsdottir K, Kingston A, Mirsky R, Jessen KR: Rat Schwann cells produce interleukin- I. J Neuroimmunol 1991;34:15-23.
48. Turka LA, Goodman RE, Rutkowski JL, Sima AA, Merry' A, Mitra RS, Wrone-SmithT, Toews G, Stricter RM, Nickoloff BJ: Interleukin-12: a potential link between nerve cells and the immune response in inflammatory disorders. Mol Med 1995:1:690-699.
49. Bolin LM, Verity AN, Silver JE, Shooter EM, Abrams JS: lnterleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochcm 1995:64:850-858.
50. Fink S, de la Barrera S, Minnucci F, Valdez R, Balina LM, Sasiain MC: IFN-y. IL-6 and IL-4 modulate M. leprae- or PPD-specific cytotoxic T cells in leprosy patients. Scand J Immunol 1993:38:551-558.
51. Baker BS, Fry L: The immunology of psoriasis. Br.J Dermatol 1992:126:1-9.
52. Kolbach DN, Nieboer C: Fumaric acid therapy in psoriasis: Results and side effect of 2 years of treatment. N Engl J Med 1995;332:581-588.
53. Gottlieb SL, Gilleaudeau P, Johnson R, Estes L, Woodworth TG, Gottlieb AB, Krueger JG: Response of psoriasis to a lymphocyte-selective toxin (DAB38911-2) suggests a primary immune, but not keratinocyte. pathogenic basis. Nat Med 1995:1:442-447.
54. Thio MB, van der Schroeff JG, Nugtercn-Huy-ing WM, Vermeer BJ: Long-term systemic therapy with dimethylfumarate and monoethylfum-arate (Fumaderm) in psoriasis. J Eur Acad Dermatol Vencrcol 1995:4:35-40.
55. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppcrt P, Wassilew SW, Horn T, Kreysel HW, Lutz G, Barth J, Rietzschel I, Joshi RK: Antipsoriatic effect of fumaric acid derivatives. J Am Acad Dermatol 1994:30:977-981.
56. Kolbach DN, Nieboer C: Fumaric acid derivates evoke a transient increase in intracellular free calcium concentration and inhibit proliferation of human keratinocytcs. J Am Acad Dermatol 1992:27:769-771.
57. Peelers AJ, Dijkmans BAG, van der Schroeff JG: Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-con-troled study. BrJ Rheumatol 1992:31:502-504.
58. Nibbcring PH, Thio B, Zomerdijk TPL, Beze-mer AC, Beijersbergen RL, van Furth R: Effects of monomethyl fumarate on human granulocytes. J Invest Dermatol 1993:101:37-42.
59. Perez VL, Lederer JA, Lichtman AH, Abbas AK: Stability of Th 1 and Th2 populations. Int Immunol 1995;7:869-875.
60. Khoruts A, Miller SD, Jenkins MK: Ncuroanti-gen-spccific Th2 cells are inefficient suppres-sorsofexperimental encephalomyelitis induced by effector Till cells. J Immunol 1995:155: 5011-5017.
61. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Pcrus-sia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor, a cytokine with multiple biologic effects on human lymphocytes. J F.xp Med 1989; 170:827-845.
62. Trinchieri G: Interleukin-12: A cytokine produced by antigen-presenting cells with immu-norcgulatory functions in the generation of T-lielper cells type I and cytotoxic lymphocytes. Blood 1994;84:4008-4027.
63. Hsieh C, Macatonia SE, Tripp CS, Wolf SI, O’Garra A, Murphy KM: Development ofThl CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993:260: 547-549.
64. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Ormc IM: Disseminated tuberculosis in IFN-y gene-disrupted mice. J Exp Med 1993:178:2243-2247.
65. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR: An essential role for IFN-y in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993:178:2249-2254.
66. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR: IL-12 increases resistance ofBALB/C mice to Mycobacterium tuberculosis infection. J Immunol 1995;155:2515-2524.
67. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL: Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science 1991:254: 277-279.
68. Bacon CM, Me Vicar DW, Ortaldo JR, Rees RC, O’Shea JJ, Johnston JA: Interleukin-12 induces tyrosine phosphorylation of JAK2 and TYK2: Differential use of Janus family tyrosine kinases by IL-2 and IL-12. J Exp Med 1995:181: 399-404.
69. Jacobson NG, Szabo SI, Weber-Nordt RM, Zhong Z, Schreiber RD, Darnell JE, Murphy KM: Interleukin-12 signaling in T helper type I (fill) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (stat)3 and stat4. J Exp Med 1995:181: 1755-1762.
70. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Giri JD, O’Shea JJ: Tyrosine phosphorylation and activation of stat5. stat3, and Janus kinases by interleukins-2 and -15. Proc Natl Acad Sei USA 1995:92:8705-8709.